{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:17:56Z","timestamp":1774016276569,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-020-00371-7","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T11:04:23Z","timestamp":1608203063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Advancing digital health: FDA innovation during COVID-19"],"prefix":"10.1038","volume":"3","author":[{"given":"Kushal","family":"Kadakia","sequence":"first","affiliation":[]},{"given":"Bakul","family":"Patel","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-8448","authenticated-orcid":false,"given":"Anand","family":"Shah","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"371_CR1","unstructured":"U.S. Food and Drug Administration. Digital Health Policies and Public Health Solutions for COVID-19. https:\/\/www.fda.gov\/medical-devices\/coronavirus-covid-19-and-medical-devices\/digital-health-policies-and-public-health-solutions-covid-19 (2020)."},{"key":"371_CR2","unstructured":"U.S. Food and Drug Administration. Digital Health Innovation Action Plan. https:\/\/www.fda.gov\/media\/106331\/download (2017)."},{"key":"371_CR3","unstructured":"U.S. Food and Drug Administration. FDA Launches the Digital Health Center of Excellence. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-digital-health-center-excellence (2020)."},{"key":"371_CR4","unstructured":"U.S. Food and Drug Administration. PMA Approvals. https:\/\/www.fda.gov\/medical-devices\/device-approvals-denials-and-clearances\/pma-approvals (2018)."},{"key":"371_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jama.2018.8832","volume":"320","author":"J Shuren","year":"2018","unstructured":"Shuren, J., Patel, B. & Gottlieb, S. FDA regulation of mobile medical apps. JAMA 320, 337\u2013338, https:\/\/doi.org\/10.1001\/jama.2018.8832 (2018).","journal-title":"JAMA"},{"key":"371_CR6","unstructured":"U.S. Food and Drug Administration. Guidances With Digital Health Content. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/guidances-digital-health-content (2020)."},{"key":"371_CR7","unstructured":"U.S. Food and Drug Administration. Digital Health Software Precertification (Pre-Cert) Program. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/digital-health-software-precertification-pre-cert-program (2020)."},{"key":"371_CR8","unstructured":"U.S. Food and Drug Administration. FDA Clears Mobile Medical App to Help Those With Opioid Use Disorder Stay in Recovery Programs. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-mobile-medical-app-help-those-opioid-use-disorder-stay-recovery-programs (2018)."},{"key":"371_CR9","unstructured":"U.S. Food and Drug Administration. FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-game-based-digital-therapeutic-improve-attention-function-children-adhd (2020)."},{"key":"371_CR10","unstructured":"U.S. Food and Drug Administration. Developing the Software Precertification Program: Summary of Learnings and Ongoing Activities. https:\/\/www.fda.gov\/media\/142107\/download (2020)."},{"key":"371_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jama.2020.9740","volume":"324","author":"EE McGinty","year":"2020","unstructured":"McGinty, E. E. et al. Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA 324, 93\u201394, https:\/\/doi.org\/10.1001\/jama.2020.9740 (2020).","journal-title":"JAMA"},{"key":"371_CR12","unstructured":"U.S. Food and Drug Administration. Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. https:\/\/www.fda.gov\/media\/136939\/download (2020)."},{"key":"371_CR13","unstructured":"World Health Organization. COVID-19 Significantly Impacts Health Services for Noncommunicable Diseases. https:\/\/www.who.int\/news-room\/detail\/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases (2020)."},{"key":"371_CR14","unstructured":"U.S. Food and Drug Administration. Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. https:\/\/www.fda.gov\/media\/136290\/download (2020)."},{"key":"371_CR15","unstructured":"U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. https:\/\/www.fda.gov\/media\/99447\/download (2017)."},{"key":"371_CR16","unstructured":"U.S. Food and Drug Administration. Developing a Software Precertification Model: A Working Model. https:\/\/www.fda.gov\/media\/119722\/download (2019)."},{"key":"371_CR17","unstructured":"U.S. Food and Drug Administration. Remarks by Commissioner Stephen Hahn, M.D. \u2014 The COVID-19 Pandemic \u2014 Finding Solutions, Applying Lessons Learned. https:\/\/www.fda.gov\/news-events\/speeches-fda-officials\/remarks-commissioner-stephen-hahn-md-covid-19-pandemic-finding-solutions-applying-lessons-learned (2020)."},{"key":"371_CR18","doi-asserted-by":"publisher","DOI":"10.1377\/hblog20200814.704964","author":"A Shah","year":"2020","unstructured":"Shah, A. & Hahn, S. M. The FDA response to COVID-19 at six months: regulatory innovation in the face of a pandemic. Health Aff. Blog https:\/\/doi.org\/10.1377\/hblog20200814.704964 (2020).","journal-title":"Health Aff. Blog"},{"key":"371_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/11694","volume":"21","author":"JA Andrews","year":"2019","unstructured":"Andrews, J. A. et al. Older adults\u2019 perspectives on using digital technology to maintain good mental health: interactive group study. J. Med. Internet Res. 21, e11694 (2019).","journal-title":"J. Med. Internet Res."},{"key":"371_CR20","doi-asserted-by":"publisher","DOI":"10.1377\/hblog20200715.454789","author":"S Verma","year":"2020","unstructured":"Verma, S. Early impact of CMS expansion of Medicare telehealth during COVID-19. Health Aff. Blog https:\/\/doi.org\/10.1377\/hblog20200715.454789 (2020).","journal-title":"Health Aff. Blog"},{"key":"371_CR21","unstructured":"Centers for Medicare & Medicaid Services. CY2020 Revisions to Payment Policies Under the Physician Fee Schedule. https:\/\/www.federalregister.gov\/documents\/2019\/11\/15\/2019-24086\/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-other (2019)."},{"key":"371_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0259-x","volume":"3","author":"C Marra","year":"2020","unstructured":"Marra, C. et al. Quantifying the use of connected digital products in clinical research. npj Digital Med. 3, 50 (2020).","journal-title":"npj Digital Med."},{"key":"371_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","volume":"19","author":"S Upadhaya","year":"2020","unstructured":"Upadhaya, S. et al. Impact of COVID-19 on oncology clinical trials. Nat. Rev. Drug Discov. 19, 376\u2013377 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"371_CR24","unstructured":"U.S. Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. https:\/\/www.fda.gov\/media\/136238\/download (2020)."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00371-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T01:30:47Z","timestamp":1670376647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1038\/s41746-020-00371-7","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}